◀ Back to ABL1
ABL1 — LYN
Text-mined interactions from Literome
Fiskus et al., Clin Cancer Res 2006
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Treatment with dasatinib attenuated the levels of autophosphorylated
Bcr-Abl , p-CrkL, phospho-signal transducer and activator of transcription 5 ( p-STAT5 ), p-c-Src, and p-Lyn ;
inhibited the activity of
Lyn and c-Src ; and induced apoptosis of the cultured CML cells
Wu et al., Blood 2008
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Lyn regulates
BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
Yu et al., Carcinogenesis 2008
(Cell Transformation, Neoplastic...) :
Abi1 contributes to Bcr-Abl induced leukemogenesis in part through Src family kinases, as the knock down of Abi1 expression attenuates
Bcr-Abl stimulated activation of
Lyn
Wu et al., J Natl Cancer Inst 2008
(Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative) :
LYN activation was
independent of
BCR-ABL in cells from imatinib-resistant patients
Mahon et al., Cancer Res 2008
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
In contrast, dasatinib, a dual
Bcr-Abl and Src kinase inhibitor,
inhibited the phosphorylation of both BCR-ABL and
Lyn , and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn
Tabe et al., Leukemia 2012
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Src related kinase
Lyn is known to interact with CXCL12/CXCR4 signaling and is directly
activated by p210
Bcr-Abl